Latest News

Full-service contract research organisation (CRO) Worldwide Clinical Trials has partnered with Every Cure to expedite the discovery of treatments for patients with rare diseases. Worldwide will serve as a drug development and clinical trial partner to Every Cure, a non-profit organisation that aims to ‘unlock the full potential of existing...
ST. LOUIS & SAN DIEGO – Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate...
Enabled by WuXi Biologics’ industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant breakthrough for CANbridge Pharmaceuticals and WuXi Biologics in advancing R&D...
UPTON, NY – Researchers at the U.S. Department of Energy’s (DOE) Brookhaven National Laboratory have demonstrated a new, highly detailed x-ray imaging technique that could be developed into a method for early diagnosis of Alzheimer’s disease. The technique has previously been used to look at tumors in breast tissue and...
X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system,  announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”).
CHICAGO, Illinois — Xentria, Inc., a clinical-stage biotherapeutics company, today announced its proposed next-stage clinical development plan for XTMAB-16, an investigational anti-tumor necrosis factor alpha, being evaluated in pulmonary sarcoidosis, a rare disease for which no anti-TNFα is currently approved by the U.S. Food and Drug Administration.     Following an end-of-phase meeting,...
Chicago, Illinois – Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of its global XTMAB16 Study in pulmonary sarcoidosis, an immune-mediated inflammatory disorder with few available treatment options. The dose-ranging study successfully enrolled 39...